Abeona Surges After FDA Clears First Gene Therapy For Severe Genetic Skin Disease

Abeona Therapeutics Inc.'s ABEO stock traded higher on Wednesday.The Food and Drug Administration (FDA) on Tuesday approved Abeona’s Zevaskyn (prademagene zamikeracel) gene-modified cellular sheets, also known as pz-cel, as the first and only autologous cell-based gene therapy for wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB).Zevaskyn is the only FDA-approved product to treat RDEB wounds with a single application.Zevaskyn consists of a patient's skin cells (ke ...